GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
Status:
Recruiting
Trial end date:
2021-07-31
Target enrollment:
Participant gender:
Summary
This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent
glioblastoma patients who were treated with standard concurrent chemoradiation.